Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Harvard Business School

Last Updated: September 27, 2022

Details for Patent: 8,318,802

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 8,318,802 protect, and when does it expire?

Patent 8,318,802 protects VELETRI and is included in one NDA.

This patent has nineteen patent family members in fifteen countries.

Summary for Patent: 8,318,802
Title:Epoprostenol formulation and method of making thereof
Abstract: This invention relates to a stable epoprostenol composition that can be combined with commercially available IV fluids and can be administered in its reconstituted and/or diluted form under ambient conditions of about C. for greater than 24 hours. The composition preferably contains (a) epoprostenol or a salt thereof; (b) a alkalinization agent; and (c) a base, such that when reconstituted or in solution, the solution has a pH>11. Methods for making the lyophilized composition are also disclosed.
Inventor(s): Palepu; Naglesh R. (Southampton, PA)
Assignee: Actelion Pharmaceuticals Ltd. (Altschwil, CH)
Application Number:12/278,061
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,318,802
Patent Claim Types:
see list of patent claims
Composition; Formulation;

Drugs Protected by US Patent 8,318,802

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Actelion VELETRI epoprostenol sodium INJECTABLE;INJECTION 022260-002 Jun 28, 2012 AP2 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Actelion VELETRI epoprostenol sodium INJECTABLE;INJECTION 022260-001 Jun 27, 2008 AP2 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,318,802

PCT Information
PCT FiledFebruary 02, 2007PCT Application Number:PCT/US2007/002948
PCT Publication Date:August 16, 2007PCT Publication Number: WO2007/092343

International Family Members for US Patent 8,318,802

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Brazil PI0707488 See Plans and Pricing
Canada 2641393 See Plans and Pricing
Canada 2868998 See Plans and Pricing
China 101410119 See Plans and Pricing
Cyprus 1117128 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.